Hansoh Pharmaceutical (300199.SZ) Enters into Joint Development Agreement for GLP-1R/GIPR/GCGR Triple Agonist Peptide Drug

Intelligent Finance APP News, Hybio Pharmaceutical (300199.SZ) announced that on May 9, 2025, the company held the fourth meeting of the sixth board of directors, and reviewed and approved the "Proposal on Signing." The company agreed to sign a joint development agreement with Shenzhen iCarbonX All Peptide Drug Technology Co., Ltd. ("iCarbonX All") for the GLP-1R/GIPR/GCGR triple agonist peptide innovative drug. Based on the preliminary cooperation results, in order to further promote the project progress, both parties plan to deepen the cooperation and jointly develop peptide innovative drugs. The dosage forms of peptide drugs include but are not limited to injections, oral preparations, etc., which are applied in the treatment of metabolic diseases such as weight control.